Calumet selling 3 million shares in secondary offering
Calumet Specialty Products Partners LP is selling 3 million shares of common stock to pay debt and to finance requirements
of an agreement with another company.
Home » Search
Search Results
199 results for 'Barclays'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
‘Most accurate’ forecaster predicts surge
A rising stock market will prompt consumers to start spending again, says Barclays economist Dean Maki.
WellPoint stock surging on positive analyst forecasts
The long-term outlook for health care reform is uncertain, but many analysts are expecting big health insurers like Indianapolis-based
WellPoint to benefit in 2010.Simon Property Group rolls out $2.25B offering
Proceeds from the offering will be used for general corporate purposes and to fund the purchase of senior notes.
PNC profit rises despite growing loan losses
The bank’s $1.01 billion in profit and its $5.08 billion in revenue were better than analysts expected.
CBS sells out Super Bowl advertising slots
More than a dozen first-timers will kick off ad campaigns with spots purchased during the Super Bowl on Sunday, making up
for holes left by Priceline.com and Toyota.HHGregg’s faster growth boosts risk, potential rewards
HHGregg Inc. had been in business nearly a half century when it hit the 50-store mark in 2004. It plans to open nearly
that number within the next year.Brookfield deal doesn’t put Simon out of General Growth game
The bid by Simon Property was an “initial salvo” and the Brookfield plan likely will prompt a new offer from the Indianapolis-based
mall owner, real estate research analyst says.Big stock run-up puts pressure on HHGregg to deliver
High expectations already are baked into HHGregg Inc.’s stock price, which has doubled since last May. A disappointment could
spawn a sell-off.Diagnostics division to help Lilly tailor treatments
Eli Lilly and Co. is launching a diagnostics division to produce tests that can winnow out the patients most likely to benefit
from a Lilly drug.Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.Court defeat lost in Lilly’s gloomy long-term outlook
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.Battery-maker EnerDel eyes utility power-storage market
Locally based EnerDel Inc. has been riding high on prospects its lithium-ion batteries will be in hot demand to power plug-in
electric vehicles, but another market might be larger. A Piper Jaffray report estimates the global market for batteries used
to store electricity on utility power grids could be $600 billion over 10 years.Lilly braces for plunge in profits
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it’s hard to picture what the company will look like in five years.ITT, other for-profit education firms face more oversight
Shares in ITT Educational Services Inc., based in Carmel, declined 13 percent Monday morning, to $56.02 each, after being downgraded
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.Lending overhaul could be trouble for ITT
New student-lending rules proposed by the Obama administration could wipe out as much as two-thirds of profits at Carmel-based
ITT Educational Services Inc., some analysts believe.Lilly investing up to $150M in VC funds
The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.
Eli Lilly will have to beat odds to meet drug-rollout goals
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
CNO Financial plans $300 million sale of debt
Carmel-based CNO Financial Group Inc., the insurer formerly known as Conseco Inc., plans to sell $300 million of seven-year senior-secured notes, according to a company statement.